1). Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003. 53:5–26.
Article
2). Dyer MJ., Hale G., Hayhoe FG., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989. 73:1431–9.
Article
3). Giles FJ. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev Anticancer Ther. 2002. 2:630–40.
Article
4). Wellhausen SR., Peiper SC. CD33: biochemical and biological characterization and evaluation of clinical relevance. J Biol Regul Homeost Agents. 2002. 16:139–43.
5). Bernstein ID. CD33 as a target for selective ablation of acute myeloid leukemia. Clin Lymphoma. 2002. 2(Suppl 1):S9-S11.
Article
6). Jacobson BS., Stolz DB., Schnitzer JE. Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nat Med. 1996. 2:482–4.
Article
7). Harvey S., Zhang Y., Landry F., Miller C., Smith JW. Insights into a plasma membrane signature. Physiol Genomics. 2001. 5:129–36.
Article
8). Sabarth N., Lamer S., Zimny-Arndt U., Jungblut PR., Meyer TF., Bumann D. Identification of surface proteins of Helicobacter pylori by selective biotinylation, affinity purification, and two-dimensional gel electrophoresis. J Biol Chem. 2002. 277:27896–902.
Article
9). Jang JH., Hanash S. Profiling of the cell surface proteome. Proteomics. 2003. 3:1947–54.
Article
10). Wilbur DS., Pathare PM., Hamlin DK, et al. Development of new biotin/streptavidin reagents for pretar-geting. Biomol Eng. 1999. 16:113–8.
11). Diamandis EP., Christopoulos TK. The biotin-(strept) avidin system: principles and applications in biotechnology. Clin Chem. 1991. 37:625–36.
12). Gharahdaghi F., Weinberg CR., Meagher DA., Imai BS., Mische SM. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis. 1999. 20:601–5.
Article
13). Belov L., de la Vega O., dos Remedios CG., Mulligan SP., Christopherson RI. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res. 2001. 61:4483–9.
14). Freedman AS. Cell surface antigens in leukemias and lymphomas. Cancer Invest. 1996. 14:252–76.
Article
15). Kishihara K., Penninger J., Wallace VA, et al. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell. 1993. 74:143–56.
Article
16). Jennings CD., Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997. 90:2863–92.
Article
17). Jiang XM., Fitzgerald M., Grant CM., Hogg PJ. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. J Biol Chem. 1999. 274:2416–23.
Article
18). Tager M., Kroning H., Thiel U., Ansorge S. Membrane-bound proteindisulfide isomerase (PDI) is in-volved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells. Exp Hematol. 1997. 25:601–7.
19). Lawrence DA., Song R., Weber P. Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation. J Leukoc Biol. 1996. 60:611–8.
Article
20). Dill KA., Chan HS. From Levinthal to pathways to funnels. Nat Struct Biol. 1997. 4:10–9.
Article
21). Ellis RJ. The general concept of molecular chaper-ones. Philos Trans R Soc Lond B Biol Sci. 1993. 339:257–61.
Article
22). Harada M., Kimura G., Nomoto K. Heat shock proteins and the antitumor T cell response. Biotherapy. 1998. 10:229–35.
Article
23). Vabulas RM., Braedel S., Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem. 2002. 277:20847–53.
Article
24). Vabulas RM., Ahmad-Nejad P., Ghose S., Kirschning CJ., Issels RD., Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002. 277:15107–12.
Article